Latest Health News

Toys’R’Us ANZ Limited has appointed voluntary administrators after abandoning its recapitalisation efforts, with ASX trading suspended immediately. The company aims to explore restructuring or sale options while maintaining operations.

Coronado Global Resources is in confidential talks with Stanwell Limited about revising coal supply agreements and securing a potential $150 million loan to bolster liquidity. While discussions are ongoing, no deal has been finalized.

Tyro Payments has announced the resignation of CEO Jon Davey, who will remain for up to six months to ensure a smooth leadership transition. Davey’s tenure saw significant transformation and strategic groundwork for future expansion.

Catapult Group International has acquired Perch, an AI-driven athlete monitoring startup, for US$18 million, enhancing its Performance & Health vertical without raising capital. This move integrates gym-based strength data with on-field analytics, promising a more comprehensive sports technology platform.

Cardiex Limited has successfully raised $2.4 million through an institutional placement to boost manufacturing and commercial activities for its CONNEQT Pulse device.

Anagenics Limited’s proprietary hair regrowth technology powers the newly launched Bouf Haircare brand, which has achieved over $500,000 in sales in its first week, setting the stage for a lucrative royalty stream.

Xstate Resources has disposed of its 20% stake in the Austrian Anshof project, eliminating liabilities and streamlining its portfolio ahead of a planned ASX re-listing and development of its Diona project in Queensland.

Challenger Gold Limited has voluntarily suspended its ASX trading pending a significant capital raising announcement, signaling potential strategic moves ahead.

BetMakers Technology Group reports solid Q3 FY25 financial gains alongside a strategic binding agreement to acquire Nevada’s LVDC, expanding its global racing technology footprint.

Kore Potash is advancing negotiations on a critical financing term sheet with the Summit Consortium for its Congo potash projects, signaling a pivotal step toward project development.

Tasmea Limited has declared a fully franked special dividend of 12 cents per share, reflecting robust financial performance and strong confidence in future growth prospects.

Recce Pharmaceuticals has completed a A$15.8 million capital raise to fund pivotal Phase 3 clinical trials and progress its FDA application, positioning the company for potential commercial breakthroughs in antibiotic-resistant infections.